This approval paves the way for SELARSDI to further align its label with the indications of the reference product Stelara (ustekinumab) in the U.S. at launch, which is expected in the first quarter of 2025.
Alvotech, Teva Reports FDA Approval For SELARSDI (Ustekinumab-aekn) In New Presentation, 130 Mg/26 Ml (5 Mg/Ml) Solution In Single-dose Vial For Intravenous Infusion
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated